Comparing Quality of Recovery Between ESPB and IV Lidocaine After Major Breast Cancer Surgery

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

July 17, 2025

Study Completion Date

July 20, 2025

Conditions
Breast Neoplasms
Interventions
DRUG

USG ESPB

"After obtaining the appropriate sonographic window, under strict aseptic precautions, the block needle is inserted in the plane of the US beam in a caudad to cranial direction until the tip is in contact with the transverse process (TP) at its lateral aspect. A test bolus of 0.9% saline (1-2 ml) is injected and sonographic evidence of erector spinae muscle displacement (posterior) from the underlying TP is sought to ensure that the tip of the block needle is indeed at the erector spinae muscle plane. The study drug from the 25 ml syringe with the label 'study drug for ESPB' (containing either 25 ml of 0.5% ropivacaine with 1:200,000 adrenaline or 0.9% saline depending on the group allocation) is injected in small aliquots over a minute. The anaesthesiologist performing the block and the patient is blinded to the group allocation.~Successful injection reveals a clearly delineated posterior displacement of the erector spinae muscle."

DRUG

Intravenous Infusion

"Following ultrasound-guided erector spinae plane block (USG ESPB), patients will be transferred to the operating room. General anesthesia (GA) will be administered according to a standardized protocol.~Study Drug Infusion:~Immediately after securing the airway, an intravenous infusion from a 50 ml syringe labeled study drug for IVI will commence. The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation. The infusion begins with a bolus rate of 0.1 ml/kg over 10 minutes and continues at 0.1 ml/kg/hr until surgical wound closure."

Trial Locations (2)

999077

North District Hospital, Sheung Shui

Unknown

The First Affiliated Hospital, Guangzhou

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT06490718 - Comparing Quality of Recovery Between ESPB and IV Lidocaine After Major Breast Cancer Surgery | Biotech Hunter | Biotech Hunter